LYNPARZA (AstraZeneca Pty Ltd)
Product name
LYNPARZA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
231 working days (255)
Active ingredients
olaparib
Registration type
EOI
Indication
LYNPARZA (tablets) is now also indicated as a monotherapy for the maintenance treatment of adult patients with platinum- sensitive relapsed high grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) after platinum-based chemotherapy. Prior treatment must have included at least 2 courses of platinum-based regimens.